Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Keple...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York (New York, Etats-Unis), le 31 juillet 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique ("NASH") et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de...
A director at Solvay SA bought 30,042 shares at 27.740EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Below are the key highlights from the conference call. Solvay's 1Q25 uEBITDA dropped 15% to € 230m, in line with the recent profit warning. Solvay reiterated the (recently cut) FY25 underlying EBITDA guidance of € 880-930m (c. -12% at midpoint vs the previous € 1.0-1.05bn range), citing continued soft demand in a context of tariff and geopolitical uncertainty. Solvay had already stated to maintain FCF guidance of c. € 300m (on the back of more prudent capex spending) which however still means th...
We updated our model after 2Q25 showed quarter-on-quarter improvement in both sales and margins. Sales reached € 211.6m, outperforming our estimate of € 200.3m and CSS's forecast of €201.9m. Customers continued to reduce their inventories during the quarter, and Melexis successfully fulfilled the resulting uptick in short-term orders. Melexis noted that 2Q25 sales exceeded expectations, driven by sequential growth in China and EMEA. From an application standpoint, strong performances were record...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.